Results 81 to 90 of about 1,565,970 (254)

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the SpA spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.
Natalie Frede, Nils Craig‐Müller, Silke Kohrt, Marei‐Theresa Bott, Ulrich Salzer, Ana Cecilia Venhoff, Jens Thiel, Julia Frede, Reinhard E. Voll, Marta Rizzi, Raquel Lorenzetti, Nils Venhoff   +11 more
wiley   +1 more source

Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database

Therapeutics and Clinical Risk Management, 2022
Takeo Hata,1 Atsushi Hirata,2 Ryosuke Ota,2 Keiko Hosohata,3 Masami Nishihara,1 Masashi Neo,1 Takahiro Katsumata1 1Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan; 2Department of Pharmacy, Kindai ...
Hata T, Hirata A, Ota R, Hosohata K, Nishihara M, Neo M, Katsumata T   +6 more
doaj  

Perfil dos usuários de anticitocinas disponibilizadas pelo Sistema Único de Saúde no estado do Paraná para o tratamento da artrite reumatoide Profile of users of anticytokines off ered by the health care system in the state of Paraná for the treatment of rheumatoid arthritis

Revista Brasileira de Reumatologia, 2012
INTRODUÇÃO: O tratamento da artrite reumatoide (AR) no âmbito do Sistema Único de Saúde (SUS) tem financiamento do Ministério da Saúde e cofinanciamento das Secretarias Estaduais.
Astrid Wiens, Mônica Cavichiolo Grochocki, Deise Regina Sprada Pontarolli, Rafael Venson, Cassyano Januário Correr, Roberto Pontarolo   +5 more
doaj   +1 more source

A Review on Liposome Encapsulated Curcumin for Treatment of Arthritis [PDF]

, 2019
The most common treatments for rheumatoid arthritis include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease modifying antirheumatic drugs (DMARDs), and some biological agents.
Sharma, Vijay, Gupta, Avinash Kumar, Gupta, Manish Kumar, Khusbu, ,   +3 more
core   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group, Kimme L. Hyrich   +8 more
wiley   +1 more source

Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease [PDF]

The Korean Journal of Internal Medicine
Background/Aims To compare the effects of abatacept and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on the progression and development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Kyung-Ann Lee, Bo Young Kim, Sung Soo Kim, Yun Hong Cheon, Sang-Il Lee, Sang-Hyon Kim, Jae Hyun Jung, Geun-Tae Kim, Jin-Wuk Hur, Myeung-Su Lee, Yun Sung Kim, Seung-Jae Hong, Suyeon Park, Hyun-Sook Kim   +13 more
doaj   +1 more source

Drug use monthly measured by DDD/1000P in (C01) Cardiac therapy, (C02) Antihypertensives, (C07) Beta-blocking agents, (M01) Antiinflammatory and antirheumatic products, and (M04) Antigout preparations from January 2016 to December 2022.

Drug use monthly measured by DDD/1000P in (C01) Cardiac therapy, (C02) Antihypertensives, (C07) Beta-blocking agents, (M01) Antiinflammatory and antirheumatic products, and (M04) Antigout preparations from January 2016 to December 2022.
Nguyen Dang Tu Le (10024031), Minh-Anh Le-Dang (17817332), Hien Pham Thu (17817341), Luyen Pham Dinh (17817335), Dinh Thanh Le (17817344), Hai-Yen Nguyen-Thi (9963037), Danh Le Ngoc (17817338)   +6 more
core   +1 more source

Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran

, 2022
INTRODUCTION: During the SARS-CoV-2 virus pandemic, immunosuppressive agents in treating chronic disease have become a concern, and rheumatic patients are not an exception.
Mirfeizi, Zahra, Firoozabadi, Mona, Zhaleh Shariati-Sarabi, Shariati-Sarabi, Zhaleh, Zahra Mirfeizi, Dadgar Moghadam, Malihe, Hashemzadeh, Kamila, Malihe Dadgar Moghadam, Sahebari, Maryam, Kamila Hashemzadeh, Mona Firoozabadi, Maryam Sahebari   +11 more
core   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

A cross-sectional survey of hepatitis B virus screening in patients who received immunosuppressive therapy for rheumatoid arthritis in Japan

Journal of Pharmaceutical Health Care and Sciences
Background Patients with a history of hepatitis B virus (HBV) infection who are receiving immunosuppressive therapy are at risk of HBV reactivation and disease.
Yuki Yanagisawa, Shungo Imai, Hayato Kizaki, Satoko Hori   +3 more
doaj   +1 more source